Hypothesis

Age‑associated increases in circulating phenylacetic acid (PAA) produced by gut microbes directly promote endothelial senescence, which in turn upregulates tissue factor (TF) and drives thrombin generation, independent of classic inflammatory pathways. Consequently, lowering gut‑derived PAA should reduce coagulant activity and extend healthspan.

Mechanistic Rationale

Recent work shows that age-associated shifts in the gut microbiota elevate circulating phenylacetic acid (PAA), which directly causes endothelial cell senescence 1. This endothelial senescence parallels the rise in PAA during aging and correlates with increased von Willebrand factor and Factor VIII, key drivers of thrombotic risk 1. While age‑related dysbiosis also elevates circulating LPS and reduces butyrate 2, these pathways have been primarily linked to neuroinflammation rather than coagulation. PAA enters the portal circulation and reaches systemic endothelium where it (1) inhibits endothelial nitric oxide synthase (eNOS) through S‑nitrosylation, decreasing NO bioavailability and favoring a procoagulant phenotype, and (2) activates the aryl hydrocarbon receptor (AhR) in endothelial cells, leading to transcriptional up‑regulation of TF and plasminogen activator inhibitor‑1 (PAI‑1). Senescent endothelial cells also secrete SASP factors that further amplify TF expression. This dual hit creates a feed‑forward loop: endothelial senescence → ↑TF → ↑thrombin → PAR‑1 signaling → further endothelial stress.

Predictions

1. Older mice with elevated fecal PAA will show higher plasma PAA, increased endothelial p16^INK4a^ and SA‑β‑gal activity, and elevated TF‑dependent thrombin generation compared with young mice.
2. Colonization of germ‑free mice with a PAA‑producing bacterial strain will recapitulate these endothelial and coagulant phenotypes, whereas colonization with an isogenic PAA‑deficient mutant will not.
3. Pharmacological scavenging of PAA (e.g., with a recombinant PAA‑degrading enzyme) or AhR antagonism will normalize eNOS activity, reduce TF expression, and lower thrombus formation in a FeCl3‑induced injury model without altering systemic cytokine levels.
4. Long‑term PAA reduction will prolong median lifespan and delay age‑related frailty markers in mice.

Experimental Design

• Mouse cohorts: young (3 mo), aged (20 mo), aged + PAA‑scavenger, aged + AhR antagonist, germ‑free colonized with PAA+ or PAA‑strains.
• Readouts: fecal and plasma PAA (LC‑MS), endothelial senescence (p16^INK4a^, SA‑β‑gal, γH2AX), eNOS phosphorylation and NO production (DAF‑FM), endothelial TF mRNA/protein (qPCR, flow cytometry), plasma thrombin‑antithrombin complexes, tail‑bleeding time, FeCl3 carotid artery occlusion time.
• Controls: vehicle‑treated aged mice, antibiotic‑treated to reduce overall microbiota.

Potential Outcomes

If PAA‑driven endothelial senescence is causal, PAA reduction will decouple aging from coagulant risk without necessarily improving cognition, highlighting a gut‑to‑vascular axis that operates independently of the gut‑brain axis. Failure to observe changes in TF or thrombin generation despite lowered PAA would falsify the hypothesis and suggest that other gut‑derived mediators dominate age‑related coagulopathy.

[1] https://doi.org/10.1101/2023.11.17.567594 [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC12515389/